All In Biotech

Drug Trial Radar · NCT03855917

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir

A Phase IV Open-label Multicentre International Pilot Study of 4-week Treatment With Sofosbuvir (400 mg) Plus Glecaprevir/Pibrentasvir (300mg/120mg) in Chronic HCV Treatment naïve Patients With Early Liver Disease

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Feb 11, 2020

Primary completion

Jul 31, 2029

Study completion Jul 31, 2029

Sponsor

Lead sponsor
Kirby InstituteGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Feb 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).

Conditions

  • Hepatitis C

Interventions

  • Sofosbuvir 400mg [Sovaldi]Drug

    Four weeks.

  • Glecaprevir/pibrentasvir (300mg/120mg)Drug

    Four weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SVR12Time frame: 16 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • St Vincent's Hospital

    Darlinghurst, New South Wales, Australia · Recruiting

  • Blacktown Mt Druitt Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.